Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer-2
Ubated with survivin-2B peptide (B), many spots were visualized. These findings demonstrate that CD8-positive T cells separated from the patients' PBMCs had a peptide-specific IFN-γ response.<p><b>Copyright information:</b></p><p>Taken from "Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer"</p><p>http://www.translational-medicine.com/content/6/1/24</p><p>Journal of Translational Medicine 2008;6():24-24.</p><p>Published online 10 May 2008</p><p>PMCID:PMC2430193.</p><p></p
